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Abstract1
To assess the impact of screening programmes in reducing the prevalence of2
Chlamydia trachomatis, mathematical and computational models are used as a3
guideline for decision support. Unfortunately, large uncertainties exist about the4
parameters that determine the transmission dynamics of C. trachomatis. Here, we5
use a SEIRS (susceptible-exposed-infected-recovered-susceptible) model to criti-6
cally analyze the turnover of C. trachomatis in a population and the impact of a7
screening programme. We perform a sensitivity analysis on the most important8
steps during an infection with C. trachomatis. Varying the fraction of the infections9
becoming symptomatic as well as the duration of the symptomatic period within10
the range of previously used parameter estimates has little effect on the transmis-11
sion dynamics. However, uncertainties in the duration of temporary immunity and12
the asymptomatic period can result in large differences in the predicted impact of13
a screening programme. We therefore analyze previously published data on the14
persistence of asymptomatic C. trachomatis infection in women and estimate the15
mean duration of the asymptomatic period to be longer than anticipated so far,16
namely 433 days (95% CI: 420–447 days). Our study shows that a longer duration17
of the asymptomatic period results in a more pronounced impact of a screening18
programme. However, due to the slower turnover of the infection, a substantial19
reduction in prevalence can only be achieved after screening for several years or20
decades.21
2
Introduction22
Infection with Chlamydia trachomatis is the most common bacterial sexually transmit-23
ted disease in many developed countries (World Health Organization, 2001). In women,24
infection can lead to pelvic inflammatory disease (PID) which can result in chronic25
pelvic pain, ectopic pregnancy or infertility (Cates and Wasserheit, 1991). Whilst acute26
infection can cause urethral discharge and pain on urination in men and symptoms such27
as vaginal discharge in women, most infections are asymptomatic and therefore remain28
undiagnosed. Screening and treatment of young adult women (Centers for Disease Con-29
trol and Prevention, 2006) or women and men (Department of Health, 2004) is widely30
promoted as an intervention to reduce the duration of infection and thus lower the31
prevalence of C. trachomatis and reduce the incidence of possible sequelae.32
Mathematical and computational models that describe the transmission of C. tra-33
chomatis have been applied to inform and guide public health decisions about screening34
programmes (Kretzschmar et al., 1996, 2001; Turner et al., 2006a; Low et al., 2007;35
Regan et al., 2008). Other models have been used to investigate aspects of immunity36
(Brunham et al., 2005), to assess the potential impact of vaccines (Gray et al., 2009) or37
to gain general insights into the transmission dynamics of C. trachomatis (Sharomi and38
Gumel, 2009). Since transmission occurs through sexual contact and screening strategies39
can be targeted to women only, women and men or specific core groups, many models40
incorporate detailed descriptions of contact patterns between people. However, there41
are great uncertainties about the parameters that describe sexual behavior and the val-42
ues used for disease-specific parameters. These have led to conflicting results about the43
potential impact of screening programmes (Kretzschmar et al., 2009). It is therefore44
essential to critically investigate the impact of different parameter assumptions in order45
to quantify the transmission dynamics of C. trachomatis and the potential impact of46
public health interventions.47
In a simple epidemiological model, the basic reproductive number, R0, determines48
the endemic prevalence of an infection. R0 can be defined as the product of the duration49
of an infection and the rate at which an infected individual transmits the disease to a sus-50
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ceptible. Whereas the first is a disease-specific parameter, the latter is also influenced51
by behavioral parameters that describe contacts between people. Hence, for a given52
prevalence of C. trachomatis within the population, the overall turnover of the infection53
is simply determined by the duration of the infection, i.e., is given by disease-specific54
parameters only. By treating the rate at which individuals engage in sexual contacts55
as a function of the endemic prevalence, we can analyze carefully the parameters that56
characterize the transitions through an infection and their influence on the predicted57
impact of a screening programme. Generally, the longer a person is infected, the more58
likely it is that they will be reached by a screening programme and will receive treat-59
ment. C. trachomatis infection is indeed characterized by a long asymptomatic period60
(Molano et al., 2005), but the duration of this period is not known. In addition, it is61
unclear what fraction of infections will cause symptoms that prompt treatment seeking62
behavior (Korenromp et al., 2002), or whether natural clearance is followed by a period63
of temporary immunity (Brunham and Rey-Ladino, 2005). Previous studies have inves-64
tigated the impact of disease-specific parameters on the impact of different screening65
strategies (Hu et al., 2006; Regan et al., 2008). Unfortunately, due to the complexity of66
these models, it is difficult to perform sensitivity analysis over a wide range of parameter67
values.68
The objective of this paper is to perform a sensitivity analysis of disease-specific69
parameters on the predicted impact of a screening programme. To this end, we devise a70
basic epidemiological model of C. trachomatis transmission dynamics that describes the71
overall turnover of the infection within a general population. In addition, we also derive72
a new estimate of the duration of the asymptomatic period by reanalyzing previously73
published data on the persistence of C. trachomatis in asymptomatically infected women.74
We discuss the implications of our results, which highlight the importance of continued75
evaluation of parameter estimates for mathematical and computational models that aim76
to assess the impact of screening programmes.77
4
Methods78
SEIRS model79
We used a SEIRS (susceptible-exposed-infected-recovered-susceptible) model, which is80
widely used in the infectious disease modeling literature (Anderson and May, 1991; Diek-81
mann and Heesterbeek, 2000; Keeling and Rohani, 2008), to devise a simple mathemat-82
ical model of C. trachomatis transmission that takes into account the major transitions83
of infected people during an infection.84
We assume a closed population where susceptibles, S, may become infected with85
C. trachomatis. They move through an incubation time, E, of the pathogen to become86
either asymptomatically, Ia, or symptomatically infected, Is. Asymptomatic people that87
recover naturally, R, may develop temporary immunity against re-infection. Symptomat-88
ically infected people have a shorter period of infection that can be ascribed to treatment89
seeking due to symptoms. Both asymptomatically and symptomatically infected people90
can get screened and directly treated (Fig. 1). Although most infections with C. tra-91
chomatis happen through sexual contacts between women and men, we strictly assume92
a homogeneous population where both genders become infected and pass through the93
infected stages at equal rates. This is a valid assumption because, even though differ-94
ences in gender-specific parameters of C. trachomatis infection have been observed, the95
purpose of our study is a sensitivity analysis over a broad range of parameter estimates96
which is wider than the gender-specific differences. We also do not assume separate risk97
groups that exhibit different sexual behavior but we illustrate in the Appendix that a98
stochastic implementation of our model exhibits a realistic amount of heterogeneity (see99
also Discussion). The model can be described by the following set of ordinary differential100
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equations:101
dS
dt
= −β(Ia + Is)S + cIa + (rs + c)Is + µR, (1)
dE
dt
= β(Ia + Is)S − γE, (2)
dIa
dt
= fγE − (ra + c)Ia, (3)
dIs
dt
= (1− f)γE − (rs + c)Is, (4)
dR
dt
= raIa − µR. (5)
There is a wide range of published estimates for the duration of the incubation102
time, 1/γ, the fraction of infections becoming asymptomatic, f , and the duration of the103
asymptomatic and symptomatic period, 1/ra and 1/rs, respectively (Table 1). Based104
on observations from studies in mice, it has been suggested that natural clearance may105
be followed by temporary immunity of length 1/µ (Brunham and Rey-Ladino, 2005).106
The parameter c denotes the effect of screening the population where asymptomatically107
or symptomatically infected people are diagnosed and treated so that they immediately108
become susceptible again. The rate at which susceptible people have contact with in-109
fected people and in which such contact results in transmission of C. trachomatis is not110
known. In our model, this rate is given by the parameter β, where λ = β(Ia + Is) can111
be described as the ‘force of infection’. Since it is exceedingly difficult to get a direct112
estimate of β or λ, we adjust the rate at which people make a potentially infectious113
contact, β, to obtain a given prevalence of the infection in the total population.114
Assuming the prevalence of C. trachomatis to be in a steady-state, the derivatives115
of Eq. (1) – (5) can be set to zero. Since we assume a closed population, we can set116
the total population size to S + E + Ia + Is + R = 1, which allows us to express all117
compartments as fractions of the total population. By solving the system of equations118
for the prevalence p = Ia + Is, we obtain119
p =
γµ(β − a− b)
β(γµ+ aγ + aµ+ bµ)
, (6)
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where120
a =
fra(rs + c)
frs + (1− f)ra + c and b =
(ra + c)(1− f)rs
frs + (1− f)ra + c + c. (7)
The expression for the prevalence p as a function of a and b can be explained by a121
simpler SEIRS model that does not distinguish between symptomatic and asymptomatic122
states. In such a model, a denotes the rate at which infected people recover and develop123
temporary immunity and b the rate at which infected people become directly susceptible124
again. The steady-state prevalence, p, of this simpler model is directly given by Eq. (6).125
The necessary ‘infection rate’ β to obtain a given prevalence p is:126
β =
γµ(a+ b)
(1− p)γµ− p(aγ + aµ+ bµ) . (8)
By choosing a and b as in Eq. (7), we can distinguish between symptomatically and127
asymptomatically infected individuals as described in the full model from Eq. (1) – (5).128
For any given combination of disease-specific parameters, we wish to calculate the129
expected prevalence of C. trachomatis in a population that receives screening at a rate130
c. To this end, we first assume a prevalence p0 in absence of screening and denote the131
corresponding ‘infection rate’ β0 which is given by Eq. (8) for c = 0. We then calculate132
the new steady-state prevalence in the presence of screening (c > 0) by Eq. (6) with133
β0 as the ‘infection rate’. This scenario is considered to reflect the long-term impact134
of opportunistic screening, where a relatively small proportion of the total population135
is tested in health care settings. In contrast to opportunistic screening, an organized136
screening programme aims to reduce the prevalence of the infection by targeting a larger137
proportion of the population at regular intervals. Further, the reduction in prevalence138
will now depend on the time that has passed since the organized screening programme139
was introduced. To contrast this with the first scenario, we also perform numerical140
simulations starting at the pre-screening steady-state, p0, to calculate the reduction in141
prevalence after an organized screening programme (c > 0) has been active for a certain142
number of years.143
Since we can express β0 as a function of the disease-specific parameters and the144
pre-screening prevalence, we can analyze the impact of screening over a wide range of145
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parameters. To express the uncertainties of previously used estimates, we use the upper146
and lower bounds of disease-specific parameters that have been used in various models of147
C. trachomatis transmission dynamics (Kretzschmar et al., 1996; Brunham et al., 2005;148
Turner et al., 2006a; Low et al., 2007; Regan et al., 2008; Gray et al., 2009; Sharomi149
and Gumel, 2009). As baseline parameters, we use the mean value of the respective150
ranges (Table 1). Since the upper bound for the duration of temporary immunity (1/µ)151
is life long, we cannot provide the mean value of the range and therefore set the baseline152
duration of immunity arbitrarily to 90 days.153
Analytical results were derived in Mathematica (Wolfram Research, Inc., 2008) and154
numerical integrations were performed in C using the routine odeint (Runge-Kutta with155
adaptive stepsize control) from Numerical Recipes (Press et al., 1992). Code files can156
be obtained freely on request from the authors.157
Parameter estimation158
To estimate the natural clearance rate of C. trachomatis, we used data from a previously159
published study. Molano et al. (2005) analyzed data from women who had endocervical160
specimens taken every 6–9 months for up to 5 years during a follow-up study about161
human papillomavirus infection. After the end of the study, stored specimens were162
also tested for C. trachomatis from which a survival function of the persistence of C.163
trachomatis infection could be derived. The date of chlamydia clearance was defined as164
the midpoint between the last positive test and a negative test. Data about antibiotic165
treatment for chlamydia and sexual partner change that might have resulted in a new166
infection were not collected but both were thought to be rare. We devise a mathematical167
model that describes the persistence of C. trachomatis in asymptomatically infected168
women:169
dIa
dt
= −raIa + αS, (9)
dS
dt
= raIa − αS. (10)
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Here, asymptomatically infected women, Ia, can clear the infection at a rate ra. Being170
susceptible again, they are at risk of re-infection at a rate α. Molano et al. (2005) provide171
data on 82 women, all of whom are infected with C. trachomatis at the beginning, so172
we can set Ia(0) = 1 and S(0) = 0 and solve for Ia(t):173
Ia(t) =
α + rae
−(ra+α)t
α + ra
. (11)
The natural clearance rate and the re-infection rate can now be estimated by fitting Eq.174
(11) to the data from figure 1 in Molano et al. (2005). The data were digitized using175
Plot Digitizer (http://plotdigitizer.sourceforge.net) and we excluded time points within176
the first 4.5 months to ensure that all women have been tested at least once during177
the follow-up period. The model was fitted using the FindFit routine that minimizes178
the sum of squared residuals (SSR) from the software package Mathematica (Wolfram179
Research, Inc., 2008).180
Results181
Impact of an organized screening programme182
To investigate the impact of organized screening in the general population, we first183
assume the pre-screening prevalence of C. trachomatis in the population to be 5%. This184
roughly corresponds to the prevalence observed in sexually active young adults (Fenton185
et al., 2001). Now, we can follow the decrease in prevalence after the introduction186
of three different organized screening programmes (Fig. 2). Screening the population187
randomly at a rate of 0.05 per year (i.e., every individual is screened once every 20 year188
on average) reduces the prevalence of infection only slightly (solid line). Increasing the189
screening rate to 0.25 per year (individuals are screened once every 4 years on average,190
dashed line) or even 0.5 per year (individuals are screened once every 2 years on average,191
dotted line) results in a pronounced impact within 5 to 10 years of screening. Clearly,192
the longer a screening programme is in place, the more pronounced is the reduction in193
prevalence. The new steady-state prevalence that will be approached in the presence of194
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a screening programme will therefore be further reduced. In this model, screening the195
population at a rate higher than 0.1 per year would eventually be sufficient to eradicate196
the infection from the population (Fig. 3, dashed line). However, the slow decline in197
prevalence after introducing a screening programme (Fig. 2) illustrates that such a state198
can only be achieved after screening for several decades. The impact of a screening199
programme implemented for 5 years (Fig. 3, dotted line) or 10 years (Fig. 3, solid line)200
is less pronounced, highlighting the difficulties in reducing the prevalence of an infection201
that exhibits a slow turnover within a reasonable time span.202
Parameter sensitivity on the impact of screening203
Due to the large uncertainties of disease-specific parameters that determine the trans-204
mission dynamics of C. trachomatis (Table 1), it is essential to perform a sensitivity205
analysis if one wants to assess the impact of screening the general population. We have206
shown above that it is important to distinguish between the effects of a screening pro-207
gramme over different time spans. Both, the temporal impact of screening during a given208
time period and the expected long-term prevalence if screening is prolonged give impor-209
tant insights into screening strategies. For our sensitivity analysis, we thus consider two210
different screening scenarios; an organized screening programme with a screening rate of211
0.25 per year implemented for 10 years, and opportunistic screening at a rate of 0.05 per212
year, in which the new steady-state prevalence is shown after long-term implementation.213
Arguably the most critical steps during an infection with C. trachomatis are the214
fraction of infections that become asymptomatic (f) and the durations of the asymp-215
tomatic and symptomatic period, 1/ra and 1/rs, respectively. During these stages C.216
trachomatis is assumed to be infectious so changes in these values should determine the217
overall transmission within a population. Varying the fraction of infections becoming218
asymptomatic at levels greater than 20%, however, has little effect on the predicted219
outcome of a screening programme (Fig. 4A, gray area). As long as the asymptomatic220
period is substantially longer than the symptomatic period, the screening intervention221
detects mostly asymptomatically infected people and only a small proportion of trans-222
mission events is caused by symptomatic individuals. Similarly, changing the duration223
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of the symptomatic period hardly affects the impact of screening (Fig. 4B). If the du-224
ration is short, little transmission is caused by symptomatics. As the duration of the225
symptomatic period increases, it becomes more likely that symptomatically infected in-226
dividuals are also detected by the screening programme. A different picture arises when227
we vary the duration of the asymptomatic period (Fig. 4C). Here, the predicted long-228
term impact of screening is much more pronounced if the asymptomatic period is at the229
upper bound of the previously used parameter range (gray area). This property also230
holds if, for example, the fraction of infections that becomes asymptomatic is varied231
at the same time (see two-way sensitivity analysis in the Appendix ). Interestingly, the232
impact of screening for 10 years is much less affected. This is because increasing the du-233
ration of the asymptomatic period results in a slower turnover of C. trachomatis within234
the population, which will decelerate the effect of screening. We performed the same235
analysis for different pre-screening prevalences of C. trachomatis which can be found in236
different risk groups (1% – 15%, results not shown). Higher pre-screening prevalences of237
C. trachomatis imply an elevated turnover of the infection. While this does not affect238
the qualitative results of the sensitivity analysis for a long-term screening intervention,239
the effect of screening for 10 years changes. Due to the elevated turnover, the impact of240
screening for 10 years becomes effective earlier and more closely resembles the effect of a241
long-term screening programme. Thus, different durations of the asymptomatic period242
can result in a substantially different impact of screening during an intervention period243
of a few years.244
In addition, we perform a sensitivity analysis on the parameters that describe the245
stages of an infection which are not infectious, i.e., the period of temporary immunity246
after natural clearance of an asymptomatic infection (1/µ) and the incubation time247
(1/γ). Although the incubation time is generally assumed to be short (gray area),248
the sensitivity analysis illustrates that changing this parameter over a wider range of249
values can affect the predicted impact of a screening programme (Fig. 5A). For a longer250
duration of the incubation time, more infected people will be screened during the time251
when the infection is assumed not to be detectable or infectious yet. Hence, the impact252
of screening the general population at a certain rate diminishes slightly. Assuming253
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temporary immunity also results in a less pronounced impact of screening. Increasing254
the duration of temporary immunity decreases the impact of screening even more (Fig.255
5B). Regarding the wide range of immunity that has been used in different models so256
far (gray area), this effect becomes especially strong in the long-term. Here, screening257
and treating asymptomatically infected people prevents the development of temporary258
immunity and renders them susceptible immediately. This somewhat counterbalances259
the otherwise strong impact of screening.260
Estimating the duration of the asymptomatic period261
We have shown that the long-term outcome of a screening programme is most sensi-262
tive to the duration of the asymptomatic period. In the modeling literature of C. tra-263
chomatis transmission dynamics, values for this parameter range from 180 to 420 days,264
emphasizing the uncertainty. A recent study that followed a large number of asymp-265
tomatic chlamydia-infected women indicated that the infection can persist for several266
years (Molano et al., 2005). However, it was mentioned that repeated infections from an267
untreated male sex partner might have biased the data in such a way that the estimated268
duration of the asymptomatic period only serves as an upper limit. In order to test the269
assumption of re-infection and to provide a robust estimate of the natural clearance rate270
in asymptomatically infected women, we fit a mathematical model to the data (Fig. 6).271
The estimated re-infection rate is low (0.01 per year; 95% CI: -0.01–0.03 per year) which272
indicates that the data are mainly described by natural clearance. With an estimated273
clearance rate of 0.84 per year (95% CI: 0.82–0.87 per year), we obtain a mean duration274
of the asymptomatic period of 433 days (95% CI: 420–447 days).275
Discussion276
We developed a basic epidemiological model that captures the most essential transitions277
through an infection with C. trachomatis to assess the importance of disease-specific278
parameters on the impact of chlamydia screening programmes. Sensitivity analyses show279
that the duration of temporary immunity and the duration of the asymptomatic period280
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strongly affect the long-term impact of screening. Longer periods of temporary immunity281
diminish the effect of screening. A longer duration of the asymptomatic period, however,282
results in a more pronounced impact of such a programme. Using previously published283
data, we estimated the average duration of the asymptomatic period at 433 days, which284
is substantially higher than most estimates used in mathematical and computational285
models. Interestingly, previous studies have indicated an even longer duration of the286
asymptomatic period than we estimate here (McCormack et al., 1979; Morre´ et al.,287
2002). As those studies followed a much smaller number of women than Molano et al.288
(2005) and did not explicitly take the effect of re-infection into account, our new estimate289
is likely to be more robust.290
The simplicity of our model facilitates the understanding of basic properties of the291
transmission dynamics of C. trachomatis. Previous attempts to investigate C. trachoma-292
tis transmission and the potential impact of public health interventions have often been293
performed with more detailed models (Kretzschmar et al., 1996; Brunham et al., 2005;294
Turner et al., 2006a; Low et al., 2007; Regan et al., 2008; Gray et al., 2009; Sharomi295
and Gumel, 2009). However, as more complicated models can be difficult to analyze and296
interpret, it is sometimes reasonable ‘to keep it simple’ in order to address some gen-297
eral principles of the transmission dynamics of an infectious disease (May, 2004; Regan298
and Wilson, 2008). In this study, we have shown the utility of a simple epidemiological299
model, especially for performing a sensitivity analysis over a wide range of parameters.300
In contrast to our assumption of homogeneous mixing, transmission of sexually trans-301
mitted infections (STIs) has been found to be driven by ‘core groups’. This concept is302
especially important to describe the transmission of bacterial STIs with short infec-303
tious periods, such as gonorrhea (Hethcote and Yorke, 1984). However, C. trachomatis304
appears to be more evenly spread across subpopulations due to its longer duration of305
infection (Chen et al., 2009). Since we assume a homogenous population, it is worth-306
while analyzing the values of the ‘infection rate’ β that we obtained by adjusting the307
pre-screening prevalence to 5%. Changing disease-specific parameters within the range308
that has been previously used results in values of β that are between 1.3 and 3.9 per309
person per year (Fig. 9). The infection rate can be expressed as the product of the310
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sexual partner change rate and the transmission probability per partnership. Given a311
transmission probability of around 0.7 (Quinn et al., 1996), the sexual partner change312
rates are in the range of 0.9 and 2.7 per year which is in agreement with reported data313
from young adults in Britain (Johnson et al., 2001). Thus, it appears that our model314
captures the overall transmission dynamics of C. trachomatis reasonably well.315
Based on our results, we can test whether differences in the duration of the infection316
are able to explain the conflicting results that have been found in Kretzschmar et al.317
(2009). Looking at the mean duration of C. trachomatis infection in men, the model318
with the longest duration indeed predicts the largest impact of a screening programme319
(Turner et al., 2006a). In contrast, the model with the shortest duration of infection in320
men results in the smallest impact of screening (Low et al., 2007). The same pattern does321
not hold for the average duration of infection in women, however. Thus, it is likely that322
different assumptions of the underlying sexual partnership dynamics further contribute323
to the observed differences in the predicted impact of a screening programme.324
Besides the qualitative insights of this study, we can also provide some quantita-325
tive predictions. For example, the results of our study, showing that screening the326
population at a rate of 0.25 – 0.5 per year over a period of 5 – 10 years can result327
in a pronounced decrease in the prevalence of C. trachomatis, are similar to those of328
more complicated compartmental or individual-based models (Kretzschmar et al., 2001;329
Turner et al., 2006b; Regan et al., 2008). Nevertheless, quantitative conclusions from330
our model should be interpreted cautiously. Our simplifying assumptions neglect poten-331
tial effects that will counter against the effect of an organized screening programme. As332
mentioned above, we do not assume a core group with a higher sexual activity than the333
general population. High prevalences of C. trachomatis could persist in such core groups334
if they are not targeted directly. If there is ongoing transmission between the core group335
and the general population, this could diminish the effect of population-wide screening336
programmes. Further, we assume perfect screening uptake and do not explicitly consider337
sexual partnerships between people. Re-infection of treated cases within steady part-338
nerships is expected to counter the desired effect of screening (Lamontagne et al., 2007;339
Low et al., 2009). These processes and the impact of partner notification have to be340
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taken into account to fully evaluate the potential of different screening programmes. To341
investigate those questions, more sophisticated mathematical and computational models342
that treat people as individuals with current and previous partners are necessary.343
Interestingly, our analysis contrasts somewhat with the sensitivity analysis of the344
study by Regan et al. (2008). There, the duration of the asymptomatic period had less345
influence on the impact of screening than what we found here. Also, they found that346
the duration of temporary immunity only affects the reduction in prevalence through347
screening moderately. Differences between these results can be explained, at least partly,348
by the narrow ranges of parameter values investigated in the sensitivity analysis of Regan349
et al. (2008). For example, the average time to recover from an asymptomatic infection350
was assumed to be between 44 to 52 weeks, i.e., 310 to 360 days. The sensitivity analyses351
presented here covered a much wider range of parameters and our new estimate for the352
average duration of the asymptomatic period in women, 433 days, exceeds their upper353
limit. We are also able to show the effects of a wider range of assumptions about the354
duration of temporary immunity and find that it can drastically diminish the effect of355
screening. Whether natural clearance of asymptomatic infection is followed by a period356
of temporary (or partial) immunity is still a matter of debate (Brunham and Rey-Ladino,357
2005). In our model, we made the assumption that temporary immunity can only358
develop in asymptomatic individuals who clear the infection naturally. Thus, screening359
and treatment directly interfere with establishing immunity, causing a diminished effect360
of screening in our model (Brunham and Rekart, 2008). In order to fully evaluate the361
role of immunity on the impact of screening programmes, we need further insights about362
the possibility of temporary immunity to C. trachomatis infection in humans and the363
timing of its development.364
To summarize, we have shown how simple epidemiological models can give important365
insights into the transmission dynamics of C. trachomatis. Our sensitivity analysis illus-366
trates that disease-specific parameters can critically influence the impact of a screening367
programme. This emphasizes the importance of continued evaluation of parameter es-368
timates for mathematical and computational models that are used to inform and guide369
public health decisions about chlamydia screening. Based on a new estimate for the av-370
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erage duration of the asymptomatic period in women, we conclude that C. trachomatis371
exhibits a slow turnover within the sexually active population and interventions that372
aim to reduce the prevalence will only become apparent after screening for several years373
or decades.374
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Appendix383
Heterogeneity in risk behavior384
Deterministic models of infectious diseases that assume a homogenous population imply385
that all people are, on average, subject to the same behavior. In the case of the SEIRS386
model presented in Methods, it can be seen that everyone obeys the same ‘infection387
rate’ β. However, the time interval at which a susceptible makes potentially infectious388
contacts to other persons is exponentially distributed. Stochastic models can make use389
of this implicit variation if each process is drawn separately from such a distribution.390
With time, this will inevitably cause variation in peoples behavior if we could look at391
them on an individual level.392
To illustrate this effect, we implemented a stochastic version of the SEIRS model in393
an individual-based population. This method allows us to store all previous contacts of394
an individual in the memory. To keep track of all contacts of an individual (including395
the non-infectious ones), it is necessary that susceptibles not only make contacts to396
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infected people but also to other susceptibles or recovered people. For simplicity, we397
assume that all contacts happen at the same rate β and that transmission occurs in any398
case if a susceptible makes a contact to an infectious individual. The individuals can399
now be grouped according to their past history of contacts at any given time. Further,400
we can calculate the prevalence of C. trachomatis for each specific group. We use the401
baseline parameters from Table 1 and run the simulation for 100 years to approach402
the steady-state in absence of any screening intervention. The simulations were run in403
the R software environment for statistical computing (R Development Core Team, 2009)404
using the package Rstisim (Althaus et al., manuscript in preparation). For the graphical405
representation of the contact network, we use the network package (Butts et al., 2008).406
The simulation shows that people can have widely different numbers of contacts,407
exemplifying the intrinsic property of variation in the individuals behavior (Fig. 7A).408
People with no or few contacts within the last year have a lower prevalence of C. tra-409
chomatis than the average population (Fig. 7B). By chance, a small fraction of people410
will have a high number of contacts and the prevalence in those groups can be much411
higher than the average. Therefore, a stochastic implementation of our SEIRS model412
in an individual-based population illustrates that, although we assume a ‘homogenous’413
population, such models do account for a certain variation in people’s behavior.414
Two-way sensitivity analysis415
For reasons of clarity, we restricted our sensitivity analysis in the Results section to416
be univariate. However, it is important to analyze the combined effect of changing417
critical parameters. Since we found the duration of the asymptomatic period to be im-418
portant, it is natural to investigate its impact together with changing the fraction of419
infections that become asymptomatic (Fig. 8A). It can be seen that the duration of420
the asymptomatic period remains a critical parameter whereas the fraction of infections421
that become asymptomatic has little impact within the range of parameters that has422
been previously used (white dashed rectangle). We also investigated the combined ef-423
fect of varying the duration of the asymptomatic period together with the duration of424
temporary immunity (Fig. 8B). Here, both parameters strongly affect the impact of a425
17
screening programme and we observe that the predicted outcome can vary from only lit-426
tle reduction in prevalence (top left corner) to close to extinction of the infection (lower427
right corner).428
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Table 1: Parameters for C. trachomatis transmission dynamics. The baseline values of disease-
specific parameters for the SEIRS model are given as the mean values from the range of
parameters that have been used in several mathematical and computational models so far
(Kretzschmar et al., 1996; Brunham et al., 2005; Turner et al., 2006a; Low et al., 2007; Regan
et al., 2008; Gray et al., 2009; Sharomi and Gumel, 2009). As an exception, we assume 90
days for the baseline duration of temporary immunity (1/µ). Given the baseline parameter
values, we obtain β = 1.95 per person per year for the infection rate and R0 = 1.07 for the
basic reproductive number.
Parameter Range Baseline value Explanation
f [0.25,1] 0.625 Fraction of infections becoming asymp-
tomatic. Note that the fraction of infections
being asymptomatic in a population at cross-
section is given as (frs)/(ra+f(rs−ra)). As-
suming baseline parameters, this corresponds
to 93% of infected cases.
1/γ [0,28] days 14 days Incubation time, i.e., the time people are in-
fected but not yet infectious.
1/ra [180,420] days 300 days Duration of the asymptomatic period.
1/rs [30,40] days 35 days Duration of the symptomatic period.
1/µ [0,∞] days 90 days Duration of temporary immunity after natu-
ral clearance of asymptomatic infection.
p0 – 0.05 Prevalence of C. trachomatis in the absence
of screening.
c – x
365
per day Screening rate with 1/x being the average in-
terval in years at which people receive screen-
ing. Note that the fraction of people that get
screened at least once within a year is given
by 1− e−x.
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Figure 1: SEIRS model illustrating infection with C. trachomatis and subsequent transitions
through the different stages of infection. Susceptibles, S, get infected by infected people,
Ia + Is, at a rate β. They then move through an incubation period (E) at a rate γ to
become either asymptomatically infected (Ia) or symptomatically infected (Is). f denotes the
fraction of infections that become asymptomatic. Asymptomatically infected people recover
through natural clearance at a rate ra and develop temporary immunity to re-infection (R) for
a duration of 1/µ. Symptomatically infected people clear the infection at a rate rs that can be
ascribed to treatment seeking due to symptoms. Both asymptomatically and symptomatically
infected people get screened and directly treated at a rate c.
24
Figure 2: Declining prevalence of C. trachomatis after the introduction of a screening pro-
gramme. Only high screening rates can achieve a significant reduction in prevalence within a
reasonable time span. Solid line, screening rate of 0.05 per year; dashed line, screening rate of
0.25 per year; dotted line, screening rate of 0.50 per year.
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Figure 3: Prevalence of C. trachomatis as a function of the rate at which the population
receives screening. In the long-term, screening more than 10% of the population would eradi-
cate C. trachomatis from the population. Due to the slow decline in prevalence, however, this
is only expected after screening over several decades. Dotted line, prevalence after 5 years of
screening; solid line, prevalence after 10 years of screening; dashed line, new steady-state that
is expected in presence of a screening programme.
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Figure 4: (A) Prevalence of C. trachomatis as a function of the fraction of infections that
become asymptomatic. For the most reasonable estimates of f , the reduction in prevalence is
only slightly affected. (B) Prevalence of C. trachomatis as a function of the duration of the
symptomatic period. The reduction in prevalence is only slightly affected by the duration of
the symptomatic period. (C) Prevalence of C. trachomatis as a function of the duration of the
asymptomatic period. Most estimates on the duration of the asymptomatic period are within
200–400 days, which results in large differences of the predicted impact of long-term screening
programmes. In all graphs: Dotted line, baseline prevalence in the absence of a screening
programme; dashed line, long-term prevalence if the population receives screening at a rate of
0.05 per year; solid line, prevalence after screening the population at a rate of 0.25 per year
for 10 years; gray area, parameter range; black dots, baseline scenario as given in Table 1.
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Figure 5: (A) Prevalence of C. trachomatis as a function of the duration of the incubation
time, i.e., the time people are infected but not yet infectious. (B) Prevalence of C. trachomatis
as a function of the duration of temporary immunity. In all graphs: Dotted line, baseline
prevalence in the absence of a screening programme; dashed line, long-term prevalence if the
population receives screening at a rate of 0.05 per year; solid line, prevalence after screening
the population at a rate of 0.25 per year for 10 years; gray area, parameter range; black dots,
baseline scenario as given in Table 1.
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Figure 6: Persistence of C. trachomatis in asymptomatically infected women as given in
(Molano et al., 2005). Fitting a mathematical model that includes natural clearance and re-
infection (see Methods) results in a natural clearance rate of ra = 0.84 per year (95% CI:
0.82–0.87 per year) and a re-infection rate of α = 0.01 per year (95% CI: -0.01–0.03 per year).
The low re-infection rate indicates that the data is mainly described by natural clearance and
we obtain a mean duration of the asymptomatic period of 433 days (95% CI: 420–447 days).
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Figure 7: Stochastic implementation of the SEIRS model in an individual-based population.
(A) Contact network during a period of one year. For illustrative purposes, the population
size was limited to 100 which results in higher connected components compared to larger
population sizes. (B) Variation in C. trachomatis prevalence if the population is stratified by
sexual behavior. Each bar represents a risk group with a given number of contacts within
the last year. The width of the bar represents the fraction of the population that belongs
to the specific risk group (see legend). The height of the bar indicates the prevalence of C.
trachomatis within that group. The gray area within each bar corresponds to the total amount
of infections within the group. The overall prevalence is given by the dashed line. Population
size: 10’000.
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Figure 8: Two-way sensitivity analysis of disease-specific parameters on the impact of a
screening programme. The density plots describe the new steady-state prevalence of C. tra-
chomatis in the presence of a screening programme (c = 0.05 per year). (A) Varying the
duration of the asymptomatic period (1/ra) together with the fractions of infections becoming
asymptomatic (f). (B) Varying the duration of the asymptomatic period (1/ra) together with
the duration of temporary immunity (1/µ). The range of parameters that have been previously
used is outlined by the white dashed rectangle and the baseline scenario is given by the white
dots (Table 1). The white area indicates extinction of the infection from the population.
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Figure 9: Infection rate β and the mean duration of infectiousness as a function of disease-
specific parameters. Changing the fractions of infections becoming asymptomatic (A), the
duration of the symptomatic period (B) and the duration of the asymptomatic period (C)
within the range that has been previously used (gray area) results in values of β (solid lines)
that are between 1.3 and 3.9 per person per year. Taking into account symptomatic and
asymptomatic infections, the mean duration of infectiousness (f/ra + (1− f)/rs, dashed lines)
is in the range of 101–300 days.
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